文献速递自身炎症与 IgG4 相关病其他结缔组织病

卡那单抗治疗Schnitzler综合征的疗效与安全性:系统文献综述

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-25

该系统综述纳入截至2020年3月16日发表的7项研究、共34例Schnitzler综合征患者,评估卡那单抗治疗的疗效与安全性。治疗期间58.6%患者达完全缓解,其余为部分缓解;最常见不良事件为感染,1例死于非典型分枝杆菌感染所致脓毒症。卡那单抗是Schnitzler综合征有效且安全性较好的长期治疗选择。

要点

  • 卡那单抗治疗Schnitzler综合征完全缓解率58.6%,其余患者均达部分缓解。
  • 最常见不良事件为感染(n=79),1例死于非典型分枝杆菌感染所致脓毒症。
  • 累计随访253个月,5项研究随访≥12个月,支持长期疗效与安全性。

核心结论

  • 卡那单抗是Schnitzler综合征有效且安全性较好的长期治疗选择。

研究设计与样本

  • 系统检索PubMed和Embase,纳入截至2020年3月16日发表的所有类型研究。
  • 共纳入7篇文献、34例Schnitzler综合征患者,累计随访253个月。

主要发现

  • 治疗期间58.6%患者达完全缓解,其余患者均为部分缓解。
  • 1例患者死于非典型分枝杆菌感染所致脓毒症。
  • 5项研究随访时间≥12个月。

关键数值与推荐

  • 完全缓解率58.6%;部分缓解率为其余患者。

临床怎么用

  • 卡那单抗可用于Schnitzler综合征的长期治疗,需监测感染等不良事件。

局限性

  • 仅基于7篇文献、34例患者的系统综述,证据来自已发表研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis. Canakinumab is a fully human monoclonal anti-interleukin-1β (IL-1β) antibody proven to be effective in IL-1 driven autoinflammatory disorders. METHODS: We systematically searched PubMed and Embase to include all types of studies on canakinumab treatment in Schnitzler syndrome published until March 16, 2020. RESULTS: Since 2011, 7 publications have been reported on canakinumab treatment in 34 patients with Schnitzler syndrome. The cumulative follow-up was 253 months, and 5 studies had a follow-up duration of 12 months or more. A complete response during treatment was reported in 58.6% of patients; all other patients had a partial response. Two hundred and seven adverse events were reported in 23 patients. Infection (n = 79) was the most common adverse event. One patient died from sepsis due to atypical mycobacterial infection. CONCLUSION: Based on the results of the current systematic review, canakinumab is an effective long-term treatment with a favorable safety profile in patients with Schnitzler syndrome.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Betrains A, Staels F, Vanderschueren S, et al. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin Arthritis Rheum. 2020. PMID: 32502728. doi:10.1016/j.semarthrit.2020.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。